Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 2542 · Old Drugs, New Cures Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–114b Manufacturer rebate for certain drugs with prices increasing faster than inflation

+1 −1Shown
More for 42 U.S.C. § 1395w–114b
Read § 1395w–114bOnly this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1860D–14B(b)(5)(B)(ii) of the Social Security Act (42 U.S.C. 1395w–114b(b)(5)(B)(ii)) is amended by inserting a priority research drug (as designated under section 1927(c)(2)(C)(iv)) or after does not include.

§ 1395w–114b(b)Rebate amount(5)–(6)

Start of § 1395w–114b to (b)(5)(B) unchanged ·

(i) In general In the case of a part D rebatable drug that is a line extension of a part D rebatable drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the rebate amount under paragraph (1) and the inflation adjusted payment amount under paragraph (3) with respect to such part D rebatable drug and an applicable period, consistent with the formula applied under subsection (c)(2)(C) of section 1396r–8 of this title for determining a rebate obligation for a rebate period under such section.

(ii) Line extension defined In this subparagraph, the term “line extension” means, with respect to a part D rebatable drug, a new formulation of the drug, such as an extended release formulation, but does not include [inserted: a priority research drug (as designated under section 1927(c)(2)(C)(iv)) or ]an abuse-deterrent formulation of the drug (as determined by the Secretary), regardless of whether such abuse-deterrent formulation is an extended release formulation.

(C) Selected drugs In the case of a part D rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title) with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), in the case such drug is no longer considered to be a selected drug under section 1320f–1(c) of this title, for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term “payment amount benchmark period” were defined under subsection (g)(3) as the last year beginning during such price applicability period with respect to such selected drug and subparagraph (B) of paragraph (3) shall be applied as if the term “benchmark period CPI–U” were defined under subsection (g)(4) as if the reference to “January 2021” under such subsection were a reference to “January of the last year beginning during such price applicability period with respect to such drug”.

(6) Reconciliation in case of revised information The Secretary shall provide for a method and process under which, in the case where a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan submits revisions to the number of units of a rebatable covered part D drug dispensed, the Secretary determines, pursuant to such revisions, adjustments, if any, to the calculation of the amount specified in this subsection for a dosage form and strength with respect to such part D rebatable drug and an applicable period and reconciles any overpayments or underpayments in amounts paid as rebates under this subsection. Any identified underpayment shall be rectified by the manufacturer not later than 30 days after the date of receipt from the Secretary of information on such underpayment.

Rest of § 1395w–114b unchanged ·

42 U.S.C. § 1396r–8 Payment for covered outpatient drugs

+1 −11 of 2 shown
More for 42 U.S.C. § 1396r–8
Read § 1396r–8Only this section
2 changes the bill asks for here, 1 carried out
  1. Not carried out:

    Section 1927(c)(2)(C) of the Social Security Act (42 U.S.C. 1396r–8(c)(2)(C)) is amended by inserting the following new clause before the flush matter at the end:(iv) Priority research drug.— (I) Request for designation.— Not later than 90 days following the date of enactment of this clause, the Secretary shall establish and make effective a process for the manufacturer of a covered outpatient drug to request that the Secretary designate the drug as a priority research drug. (II) Designation.— Not later than 60 calendar days after the receipt of a request under subclause (I), the Secretary shall designate a covered outpatient drug as a priority research drug so long as it meets the following criteria: (aa) As of the date of submission of such request, at least 10 years have elapsed since the date the drug was approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act or section 351(a) of the Public Health Service Act. (bb) The manufacturer of the drug is investigating such drug under section 505(i) of the Federal Food, Drug, and Cosmetic Act or section 351(a)(3) of the Public Health Service Act for a new indication that would address a significant unmet medical need because there is no alternative drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of the Public Health Service Act for such indication on the date that the request under subclause (I) was submitted to the Secretary. (cc) The new indication described in item (bb) is for a disease or condition that has a high prevalence among beneficiaries of Federal health care programs. For purposes of this clause, a disease or condition has a high prevalence among beneficiaries of Federal health care programs if at least 33 percent of claims in the population targeted by the new indication during the prior calendar year were paid for under— (AA) a State plan under this title or a State child health plan under title XXI; (BB) part D of title XVIII with respect to an individual who is eligible for subsidies under section 1860D–14; (CC) the drug discount program under section 340B of the Public Health Service Act (42 U.S.C. 256b; or (DD) a health care program administered by the Department of Veterans Affairs..

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: inserting the following new clause before the flush matter at the end: QCONTENT.
  2. Carried out:

    Section 1927(c)(1)(C)(ii)(V) of the Social Security Act (42 U.S.C. 1396r–8(c)(1)(C)(ii)(V)) is amended by inserting unless such drug is also designated as a priority research drug under paragraph (2)(C)(iv) during such period before the period.

§ 1396r–8(c)(1)Basic rebate for single source drugs and innovator multiple source drugs(C)–(D)

Start of § 1396r–8 to (c)(1)(C)(ii)(III) unchanged ·

(IV) in the case of a manufacturer that approves, allows, or otherwise permits any other drug of the manufacturer to be sold under a new drug application approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)], shall be inclusive of the lowest price for such authorized drug available from the manufacturer during the rebate period to any manufacturer, wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or governmental entity within the United States, excluding those prices described in subclauses (I) through (IV) of clause (i); and

(V) in the case of a rebate period and a covered outpatient drug that is a selected drug (as referred to in section 1320f–1(c) of this title) during such rebate period, shall be inclusive of the maximum fair price (as defined in section 1320f(c)(3) of this title) for such drug with respect to such period[inserted: unless such drug is also designated as a priority research drug under paragraph (2)(C)(iv) during such period].

(iii) Application of auditing and recordkeeping requirements With respect to a covered entity described in section 256b(a)(4)(L) of this title, any drug purchased for inpatient use shall be subject to the auditing and recordkeeping requirements described in section 256b(a)(5)(C) of this title.

(D) Limitation on sales at a nominal price

Rest of § 1396r–8 unchanged ·

Step through the changes